secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K/A
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001558370-23-000424
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences appoints Dayno as Interim President and CEO; details compensation
--------------------------------------------------------------------------------

- Dr. Jeffrey Dayno appointed Interim President and CEO effective Jan 6, 2023; continues as CMO.
- Annual base salary set at $530,000; target annual bonus of 75% of base salary.
- One-time cash bonus of $300,000 payable upon earlier of June 30, 2024 or change in control.
- Upon permanent CEO appointment, Dayno reverts to EVP/CMO with base salary $530,000 and 75% target bonus.
- Executive Chairman Jeffrey Aronin to receive $500,000 annual cash payment, pro-rated quarterly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/hrmy-20230105x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-000424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer